Scientists at the University of Oxford, led by Professor Ahmed Ahmed, are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
In this study, the CRUK-funded researchers will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.
If this research is successful, work will then begin on clinical trials of the vaccine. The hope is that in the future, women could be offered this vaccine to prevent ovarian cancer in the first place.
Read the full story on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) website.
more recommended stories
Vaping and Teen Smoking: UK Study Warns of Rising RisksA new study published in Tobacco.
Targeting Cancer Cell Memory Boosts ChemotherapyResearchers double chemotherapy effectiveness through chromatin.
PFAS Exposure Linked to Increased Type 2 Diabetes RiskInvestigating the Metabolic Impact of Forever.
Gecko-Inspired Nanoparticles Offer New Direction in Localized Cancer TherapyNature-Inspired Nanoparticles Deliver Precision Chemotherapy Researchers.
Staphylococcus Shows Complex Enzyme Redundancy, Study FindsA Bacterial Pathogen That Refuses to.
Can Routine Vaccines Help Combat Antibiotic Resistance?A growing body of evidence now.
T-bet and the Genetic Control of Memory B Cell DifferentiationIn a major advancement in immunology,.
Ultra-Processed Foods May Harm Brain Health in ChildrenUltra-Processed Foods Linked to Cognitive and.
Parkinson’s Disease Care Advances with Weekly InjectableA new weekly injectable formulation of.
Brain’s Biological Age Emerges as Key Health Risk IndicatorClinical Significance of Brain Age in.
Leave a Comment